We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00317967
Recruitment Status : Completed
First Posted : April 25, 2006
Last Update Posted : December 9, 2013
Information provided by (Responsible Party):

April 24, 2006
April 25, 2006
December 9, 2013
April 2007
October 2010   (Final data collection date for primary outcome measure)
Change in left ventricular mass at 12 months from baseline [ Time Frame: 12 months ]
Change in left ventricular mass at 12 months from baseline.
Complete list of historical versions of study NCT00317967 on ClinicalTrials.gov Archive Site
  • a decrease in maximal ventricular wall cross sectional width [ Time Frame: 12 months ]
  • a decrease in the incidence of nonsustained ventricular tachycardia [ Time Frame: 12 months ]
  • a decrease in T-wave alternans [ Time Frame: 12 months ]
  • a decrease in the volume of dense myocardial fibrosis [ Time Frame: 12 months ]
  • parameters of diastolic function [ Time Frame: 12 months ]
A decrease in the incidence of nonsustained ventricular tachycardia, in T-wave alternans; in maximal ventricular wall cross-sectional width; in volume of dense myocardial fibrosis, and parameters of diastolic function at 12 months from baseline.
Not Provided
Not Provided
Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
Statin Induced Regression of Cardiomyopathy Trial - SirCat
The purpose of this study is to determine if a drug called atorvastatin will reduce the size and stiffness of the muscle in the left ventricle of the heart.
Hypertrophic cardiomyopathy (HCM) is a primary disorder of the heart characterized by a thickened, fibrotic myocardium, with or without a dynamic left ventricular outflow tract gradient. It is a common heritable cardiovascular disease, with a population prevalence of 0.1% to 0.2%. Symptoms of congestive heart failure are extremely common in patients with HCM. Progression to disabling and debilitating symptoms [New York Heart Association (NYHA) class III and IV] is relatively common, occurring in 15% to 20% of unselected populations. The rate of progression to NYHA class III or IV or death from heart failure or stroke is high, with a relative risk 2.7. Management of symptoms can be very challenging, involve multiple medications, and 5% of patients may develop drug refractory heart failure, requiring invasive intervention. HCM is the most common cause of sudden death among young competitive athletes. Ventricular tachyarrhythmias appear to be the primary mechanism; however, other arrhythmias involved include asystole, rapid atrial fibrillation, and electrical mechanical dissociation. Patients may develop progressive myocardial wall thinning, a reduction in systolic performance, and an increase in left ventricular dimensions. Progressive wall thinning may be especially common in patients with initially severe hypertrophy. There is no cure for this condition. There is now evidence from both animal and human studies of a treatment that promises to reverse hypertrophy - HMG CoA reductase inhibitors. Clearly, studies of treatments that might cause regression of hypertrophy are timely and important.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypertrophic Cardiomyopathy
  • Drug: Atorvastatin
    80 mg pills daily
  • Drug: Placebo
    80 mg pills daily
  • Experimental: 1
    Intervention: Drug: Atorvastatin
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years and over with HCM in the absence of another cardiac or systemic disease capable of producing a prespecified wall thickening

Exclusion Criteria:

  • Required use of statin therapy or intolerance
  • A clinical diagnosis of hypertension
  • Indication for statin therapy for primary or secondary prevention of coronary artery disease
  • Current or anticipated indication in ≤ 1 year for implantable cardioverter defibrillators or other metallic devices preventing cardiac magnetic resonance imaging (MRI).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Bob Sheldon, University of Calgary
University of Calgary
Heart and Stroke Foundation of Canada
Principal Investigator: Robert S. Sheldon, MD, PhD University of Calgary
University of Calgary
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP